Yes, couldn't agree more. There were many points in the report that also caught my attention.
Note also the bold emphasis on the selected in-house drug program against high value intracellular targets (with three attractive targets already identified).
I'm particularly looking forward to learning more about Phylogica's action plan moving forward this year with their PYC35 Phylomer, which will no doubt represent an interesting and near term revenue opportunity.
As I have mentioned previously, the significance of the first deal with Le Metier should not be underestimated.
1. Further licenses in this market have lower barriers to entry in terms of cost and time than the Pharma market.
2. The company will start generating multiple near-term recurring streams of revenue.
3. Phylogica will be able to offset the running costs of the company.
4. This deal will represent a big foot in the door to further licenses and much larger revenue streams moving forward.
Remember what happened to the share price when this deal was announced? Do the maths. Another one or two BIG licenses announced and I'd say Phylogica will not be far off a serious surge. In the next 12 months, we could conservatively see Phylogica sitting at many multiples of its current share price just on this market alone.
Regards, Tony
PYC Price at posting:
2.4¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)